Switzerland is a third country for medical devices, a separate pricing jurisdiction for medicines and a separate merger-control regime for deals, and none of those facts is visible from an EU compliance program. A US device maker appoints a Swiss authorized representative and registers with Swissmedic beside its EU obligations; a pharma launch meets the advertising rules of the HMG and the three-year price review; a distribution agreement runs into Switzerland's exhaustion rules; a digital-health product can use a regulatory sandbox built on guidance; and a concentration is now reviewed by the WEKO under an EU-style test. The Bilaterals III protocols signed in March 2026 leave the devices chapter of the mutual recognition agreement to an undated decision. The analyses below cover each entry point in turn.
8 insights · latest June 2026
Swiss MedTech manufacturers face EU authorized representative requirements under MDR/IVDR. Liability implications extend beyond formality.
The lapsed Mutual Recognition Agreement creates a dual regulatory burden for Swiss manufacturers. Strategies to mitigate the cost and complexity of parallel compliance.
Switzerland has been a third country for medical devices since May 2021, and the Bilaterals III protocols signed in March 2026 leave the MRA devices chapter to an undated Committee decision, so dual authorized representation persists.
Switzerland's regulatory sandbox for digital health offers flexibility through guidance rather than statute. What this means for market entry strategy and timing.
Switzerland's 2025 three-year pricing review repriced over 300 pharma products. Cascade effects on R&D investment, cantonal incentives, and market access.
Art. 32 HMG and Art. 88 of Directive 2001/83/EC prohibit public advertising of prescription medicines outright, and the AWV and VITH reach disease-awareness material, hospitality and samples, so several standard US launch programs are unlawful on arrival.
Switzerland's revised Kartellgesetz replaces the qualified-dominance test of Art. 10(2) KG with an EU-style significant-impediment standard, so WEKO merger review reaches US MedTech and pharma concentrations well short of monopoly. Notification thresholds are unchanged.
Switzerland's exhaustion rules create unique pharmaceutical distribution dynamics. Patent and trademark exhaustion interact with competition law implications.
Counsel on this topic: Swiss Authorized Representative (CH-REP) advisory.
Good questions deserve specific answers.
Get in Touch